5.png)
Sun Pharmaceuticals, a Rs. 27,700 crore plus leading Indian pharma entity, has received yet another blow from US FDA. The company's Dadra facility underwent an inspection by US FDA recently and US FDA issued a Form-483 observation letter with 11 observations. Currently, Sun Pharma is in the process of responding to the said letter to the US FDA within the stipulated timeline of 15 days.
Sun Pharma and its subsidiaries have many facilities which supply products to the US market. These facilities undergo periodic routine inspection by the US FDA in normal course of business. As indicated above, the company is in the process of responding to the US FDA for the Form-483 observation letter issued for the Dadra facility.
Sun Pharma scrip opened lower at Rs. 635.05 today as against its previous day close of Rs. 640.05.
Sun pharma gets fresh 11 observations from us fda
